LR19128

LR19128 is an investigational oncology drug candidate currently in the preclinical stage of development by LG Chem. While the specific molecular target and modality (e.g., small molecule or monoclonal antibody) have not been publicly disclosed, the asset is a component of LG Chem's strategic expansion into the oncology therapeutic area. The company's oncology pipeline has been significantly bolstered by its 2023 acquisition of AVEO Oncology, and LR19128 represents part of its internal R&D efforts to address high unmet needs in cancer treatment. As of early 2024, the program remains in the early discovery and preclinical validation phase.